Lv1
60 积分 2024-01-17 加入
Trispecific engager overcomes tumoural immunosuppressive environment
3个月前
已完结
A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
3个月前
已完结
Structural basis for LZTR1 recognition of RAS GTPases for degradation
9个月前
已完结
Mechanisms of genomic resistance across emerging classes of KRAS inhibitors
9个月前
已完结
Focused Structure-Based Virtual Screening Identifies Novel Inhibitors of SOS1
10个月前
已完结
Solid-State Evaluation of a Newly Emerged Polymorph for Early-Stage Pharmaceutical Development
1年前
已完结
9 Oral: BBO-10203, an orally bioavailable small molecule that disrupts the RAS-PI3Kα interaction leading to pAKT and tumor growth inhibition in models of breast, lung and colorectal cancer
1年前
已完结
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction
1年前
已完结
皖公网安备34019202002308
